AlzeCure Pharma AB
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AlzeCure Pharma AB
AlzeCure Confident Of Bagging Partner For Pain Drug
The Swedish biotech is stepping up its business development plans ahead of a mid-stage readout in the summer for ACD440, its TRPV1 antagonist for neuropathic pain.
AlzeCure Hunts For Small Molecules In Its Alzheimer’s Quest
Emerging Company Profile: Swedish biotech AlzeCure is developing a portfolio of small-molecule drug candidates for diseases affecting the central nervous system, including Alzheimer’s disease and pain.
Deal Watch: Gain To Test Enzyme-Enhancement Tech In Cancer With Zentalis
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.